Aslan Pharmaceuticals Shares Are Trading Higher On Positive ASLAN004 Data In Atopic Dermatitis

Aslan Pharmaceuticals Ltd (NASDAQ: ASLN) announces positive interim unblinded data from its ongoing Phase 1 study evaluating ASLAN004 to treat moderate to severe atopic dermatitis (AD).

  • Subcutaneous delivery of ASLAN004 was shown to be well tolerated across all doses (200mg, 400mg, and 600mg) and showed improvements compared to placebo in all efficacy endpoints.
  • At week 8, the average reduction in eczema severity index from baseline at therapeutic doses (400mg and 600mg cohorts) was 74% compared to 42% on placebo.
  • A 50% decrease in eczema index was observed in 89% ASLAN004 treated patients than 40% on placebo.
  • A 75% and 90% decrease in eczema index was seen in 67% and 56% of the patients in ASLAN004, respectively, compared to none on placebo.
  • The proportion of patients with adverse events and treatment-related adverse events were similar across treatment and placebo arms.
  • Full unblinded data from approximately 50 patients are expected in mid-2021.
  • The company plans to initiate a global Phase 2b study later this year.
  • ASLAN's management will host a webcast and conference call at 8 am ET today.
  • Price Action: ASLN shares jumped 78.3% at $7.92 in premarket trading on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksContractsFDAGeneralatopic dermatitis
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!